Treatment of Colorectal Cancer Using a Combination of Liposomal Irinotecan (Irinophore C™) and 5-Fluorouracil

Treatment of Colorectal Cancer Using a Combination of Liposomal Irinotecan (Irinophore C™) and 5-Fluorouracil

Bibliographic Details
Main Authors:	Hare, Jennifer I., Neijzen, Robert W., Anantha, Malathi, Dos Santos, Nancy, Harasym, Natashia, Webb, Murray S., Allen, Theresa M., Bally, Marcel B., Waterhouse, Dawn N.
Format:	Online
Language:	English
Published:	Public Library of Science 2013
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3633892/

Similar Items

Irinophore C™, a lipid nanoparticle formulation of irinotecan, abrogates the gastrointestinal effects of irinotecan in a rat model of clinical toxicities
by: Waterhouse, Dawn N., et al.
Published: (2014)

Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (Irinophore C™), doxorubicin (Caelyx®) or vincristine
by: Verreault, Maite, et al.
Published: (2011)

Sphingomyelin Liposomes Containing Porphyrin-phospholipid for Irinotecan Chemophototherapy
by: Carter, Kevin A, et al.
Published: (2016)

Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models.
by: Webb, M. S., et al.
Published: (1995)

A phase I dose-escalation study of PEP02 (irinotecan liposome injection) in combination with 5-fluorouracil and leucovorin in advanced solid tumors
by: Chiang, Nai-Jung, et al.
Published: (2016)

Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial
by: Seymour, Matthew T, et al.
Published: (2013)

RESEARH OF THE LIPID MEMBRANE COMPOSITION DURING LIPOSOMAL IRINOTECAN CREATION
by: O. V. Stadnichenko, et al.
Published: (2017-03-01)

Raltitrexed (Tomudex) administration in patients with relapsed metastatic colorectal cancer after weekly irinotecan/5-Fluorouracil/Leucovorin chemotherapy
by: Tsavaris, Nicolas, et al.
Published: (2002)

Irinotecan, Continuous 5-Fluorouracil, and Low dose of Leucovorin (modified FOLFIRI) as First Line of Therapy in Recurrent or Metastatic Colorectal Cancer
by: Lee, Myung-Ah, et al.
Published: (2005)

Effect of Gender on Coagulation Functions: A Study in Metastatic Colorectal Cancer Patients Treated with Bevacizumab, Irinotecan, 5-Fluorouracil, and Leucovorin
by: Bilir, Cemil, et al.
Published: (2014)

Serum iron levels as a new biomarker in chemotherapy with leucovorin and fluorouracil plus oxaliplatin or leucovorin and fluorouracil plus irinotecan, with or without molecularly-targeted drugs
by: OCHIAI, TAKUMI, et al.
Published: (2013)

Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC)
by: Souglakos, J, et al.
Published: (2012)

PEPCOL: a GERCOR randomized phase II study of nanoliposomal irinotecan PEP02 (MM‐398) or irinotecan with leucovorin/5‐fluorouracil as second‐line therapy in metastatic colorectal cancer
by: Chibaudel, Benoist, et al.
Published: (2016)

Docetaxel combined with irinotecan or 5-fluorouracil in patients with advanced oesophago-gastric cancer: a randomised phase II study
by: Roy, A, et al.
Published: (2012)

Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience
by: Danielle C. Glassman, et al.
Published: (2018-06-01)

Remarkable response to fluorouracil, leucovorin, oxaliplatin, and irinotecan therapy in urothelial cancer of the renal pelvis: a case report
by: Takuya Tsujino, et al.
Published: (2017-04-01)

Cost-effectiveness Analysis of Fluorouracil, Leucovorin, and Irinotecan versus Epirubicin, Cisplatin, and Capecitabine in Patients with Advanced Gastric Adenocarcinoma
by: Wen, Feng, et al.
Published: (2016)

A Case of Metastatic Urachal Carcinoma Treated With FOLFIRI (irinotecan and 5-Fluorouracil/leucovorin) Plus Bevacizumab
by: Kanamaru, Tomohiro, et al.
Published: (2014)

Second-Line Irinotecan, Leucovorin, and 5-Fluorouracil for Gastric Cancer Patients after Failed Docetaxel and S-1
by: Jung, Joo Young, et al.
Published: (2016)

Irinotecan plus fluorouracil‐based regimen as second or third‐line chemotherapy for recurrent or metastatic esophageal squamous cell carcinoma
by: Wang, Xi, et al.
Published: (2015)

Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors
by: Wu, Huali, et al.
Published: (2015)

A genotype-directed phase I–IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer
by: Marcuello, E, et al.
Published: (2011)

Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer
by: Kuehr, Thomas, et al.
Published: (2004)

Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer
by: Teufel, Andreas, et al.
Published: (2004)

Irinotecan-Induced Dysarthria
by: Dressel, Albertine J., et al.
Published: (2012)

Nanoscale Reaction Vessels Designed for Synthesis of Copper-Drug Complexes Suitable for Preclinical Development
by: Wehbe, Mohamed, et al.
Published: (2016)

Epidermal growth factor receptor inhibitor with fluorouracil, leucovorin, and irinotecan as an alternative treatment for advanced upper tract urothelial carcinoma: a case report
by: Lu, Yen-Man, et al.
Published: (2016)

Biodistribution and pharmacokinetics of 188Re-liposomes and their comparative therapeutic efficacy with 5-fluorouracil in C26 colonic peritoneal carcinomatosis mice
by: Tsai, Chia-Che, et al.
Published: (2011)

A phase I study of irinotecan and pegylated liposomal doxorubicin in recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 104 study)
by: Shoji, Tadahiro, et al.
Published: (2014)

Irinotecan-containing doublet treatment versus irinotecan monotherapy as second-line choice for advanced gastric cancer
by: Liuting Yang, et al.
Published: (2018-04-01)

The novel tankyrase inhibitor (AZ1366) enhances irinotecan activity in tumors that exhibit elevated tankyrase and irinotecan resistance
by: Quackenbush, Kevin S., et al.
Published: (2016)

Synergistic Effects of Simvastatin and Irinotecan against Colon Cancer Cells with or without Irinotecan Resistance
by: Jang, Hyun Joo, et al.
Published: (2016)

Identification of Sestrin3 Involved in the In vitro Resistance of Colorectal Cancer Cells to Irinotecan
by: Choi, Seung Ho, et al.
Published: (2015)

Equilibrium-fluctuation-analysis of single liposome binding events reveals how cholesterol and Ca2+ modulate glycosphingolipid trans-interactions
by: Kunze, Angelika, et al.
Published: (2013)

Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression†
by: Obermannová, R., et al.
Published: (2016)

A randomized Phase II clinical study of combining panitumumab and bevacizumab, plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) compared with FOLFIRI alone as second-line treatment for patients with metastatic colorectal cancer and KRAS mutation
by: Liu, Yuguo, et al.
Published: (2015)

Liposomal delivery and polyethylene glycol-liposomal oxaliplatin for the treatment of colorectal cancer (Review)
by: YANG, CHUANG, et al.
Published: (2014)

Formulation and Evaluation of Irinotecan Suppository for Rectal Administration
by: Feng, Haiyang, et al.
Published: (2014)

Mesostructured silica matrix for irinotecan delivery systems
by: Nastase Silviu, et al.
Published: (2014-08-01)

Effects of the protein corona on liposome–liposome and liposome–cell interactions
by: Corbo, Claudia, et al.
Published: (2016)